The Lancet Regional Health Western Pacific
HBsAg seroclearance with HBV DNA <100 IU/mL and long-term risks of adverse liver events, all-cause mortality, and cause-specific mortality in chronic hepatitis B: a prospective cohort study
Cohort study of 6,018 peopleChronic hepatitis B